InvenireX is commercialising the world’s first benchtop instrument capable of detecting and absolutely quantifying DNA and RNA at the single-molecule level, unlocking a degree of precision previously unattainable. This breakthrough enables foundational measurements across the life sciences, with applications spanning point-of-care diagnostics (for example, rapid COVID-19 or malaria testing), gene expression analysis, mutation detection, SNP genotyping, and drug discovery.

Founded in 2021 by Dr Dan Todd and based in Newcastle, InvenireX received its first investment from DSW Ventures in early 2024 – a £385k commitment as part of a £500k round alongside XTX Investments. In August 2025, DSW Ventures invested a further £385k of EIS-qualifying capital as part of a £1m seed round, complemented by £1.1m of grant funding from UKRI and the Royal Academy of Engineering. A further £414k raised in April 2026 from DSW Ventures and new co-investors, brings the company’s total funding to £3m. InvenireX is now preparing to commercialise its R.O.S.A.L.I.N.D. device.